Y mAbs Therapeutics

Yahoo Finance • last month

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceut... Full story

Yahoo Finance • last month

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy... Full story

Yahoo Finance • 2 months ago

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy a... Full story

Yahoo Finance • 2 months ago

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy a... Full story

Yahoo Finance • 2 months ago

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy a... Full story

Yahoo Finance • 8 months ago

Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top Holdings Now?

We recently compiled a list of the Top 10 Holdings of Caligan Partners.In this article, we are going to take a look at where Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) stands against Caligan Partners' other top holdings. Founded in 2017, Cal... Full story

Yahoo Finance • last year

Here's Why We're Not At All Concerned With Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have done very well over the last year, with the share price soaring by 154%. But the harsh realit... Full story

Yahoo Finance • last year

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

Y-mAbs Therapeutics, Inc NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of no... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) concerning possible breaches of fiduciary duty. To obtain additional information, go... Full story

Yahoo Finance • last year

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based ther... Full story

Yahoo Finance • last year

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based thera... Full story

Yahoo Finance • last year

Y-mAbs Announces Publication in Cancers

NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based ther... Full story

Yahoo Finance • 2 years ago

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based the... Full story

Yahoo Finance • 2 years ago

Y-mAbs to Participate at Upcoming Investor Conferences in September

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based the... Full story

Yahoo Finance • 2 years ago

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, aft... Full story

Yahoo Finance • 2 years ago

Y-mAbs Announces Presentation of Naxitamab data at AACR

Y-mAbs Therapeutics, Inc NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of no... Full story

Yahoo Finance • 2 years ago

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based ther... Full story

Yahoo Finance • 2 years ago

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022DANYELZA conditional marketing authorization granted in China Management reiterates 2023 financial gui... Full story

Yahoo Finance • 2 years ago

Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, Inc. (NASDAQ: FATE), Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), and International Business Machines Corp. (NYSE: IBM)

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Sotera Health Co. (NASDAQ: SHC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the... Full story

Yahoo Finance • 2 years ago

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, 2022, on Thursday, March 30, 2023, af... Full story